Dexmedetomidine is a promising adjunct to be considered for palliative sedation when managing end-of-life symptoms such as refractory pain, anxiety, or delirium.

This medication should be considered a reasonable alternative to traditional agents used for palliative sedation given its favorable side effect profile, especially its minimal impact on respiratory rate, allowing palliative care teams to effectively control symptoms while minimizing concern for hastening death.

Further investigation is necessary to establish protocols and dosing recommendations.

Dexmedetomidine is being increasingly recognized for its role in palliative care, specifically for palliative sedation to manage refractory symptoms such as delirium, anxiety, and pain.

Read More